Fifth International Congress Drug Therapy in HIV Infection 22-26 October, 2000 Glasgow, UK

RECURRENCE OF CMV VIRAEMIA AND DEVELOPMENT OF ANTI-CMV DRUG RESISTANCE IN PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AFTER CMV RETINITIS

J.R. Deayton, C. Shannon-Lowe, P. Wilson, M.A. Johnson, P.D. Griffiths, V.C. Emery
Royal Free and University College School of Medicine, London, UK

Int Cong Drug Therapy HIV 2000 Oct 22-26;5:Abstract No. PL5.4.2
AIDS 2000, Oct 22-26;14(Suppl. 4);S5

Patients who have received HAART and have extended survival rates following CMV retinitis (CMVR) have now had prolonged exposure to anti-CMV therapies. This study aims to identify risk factors for recurrence of CMV viraemia in such patients and to investigate the development of ganciclovir resistance associated with the long term receipt of maintenance therapy for CMVR.

Patients who received HAART following CMVR were prospectively monitored 1–3 monthly for recurrent CMV viraemia using PCR. CMV load was determined using a quantitative competitive PCR. DNA samples from patients who experienced recurrent CMV viraemia whilst on maintenance ganciclovir therapy for CMVR were sequenced for mutations in the CMV phosphotransferase gene UL97 which confer ganciclovir resistance. Eleven patients were studied. The median time from initial diagnosis of CMVR was 43 months and the median time since staring HAART 39 months. The cohort had received a median of 21 months of anti-CMV therapy. In nine patients who discontinued maintenance therapy after HAART there were no recurrences of either CMV viraemia or CMVR at a median of 25 months of follow-up. CMV viraemia recurred in three patients while on maintenance therapy; the median rebound CMV load was 3.8 × 10⁴ copies/ml. In patient 1 recurrence of viraemia was associated with hydroxyurea-induced neutropenia. CMV viraemia was cleared following a reduction in the dose of hydroxyurea. Patient 2 experienced recurrent viraemia on two occasions; in both cases viraemia was associated with multiple UL97 mutations and: cleared following HAART intensification. Patient 3 experienced increasing CMV load following failure of HAART. UL97 sequencing at this time showed the C592G mutation and a deletion of codons 590 and 591. Treatment with foscarnet and cidofovir failed to control viraemia. However, at 3 months after stopping ganciclovir the CMV genome had reverted to wild type at the above codons. Reintroduction of oral ganciclovir at this point resulted in control of CMV viraemia but was associated with the reappearance of the resistance mutations in subsequent positive samples. Recurrence of CMV viraemia is a marker of HAART failure and should prompt intensifi- cation of therapy. Patients who have received extensive maintenance therapy for CMVR have a high incidence of anti-CMV drug resistance mutations and are at risk of anti-CMV treatment failure. CMV load should be monitored frequently if re-induction therapy is required for recurrent CMVR after HAART failure. Genotyping for resistance mutations should be performed early if CMV load does not suppress rapidly following anti-CMV therapy.

Presenting author: J.R. Deayton

Download Conferences Abstracts

2000-10-22
5-4-2

Originally published in AIDS Volume 14, Supplement 4 and hosted with permission of the publisher Lippincott Williams & Wilkins, 250 Waterloo Road, London, SE1 8RD, UK. Tel: +44 (0)20 7981 0700 Fax: +44 (0) 7981 0701

Copyright © 2000 - Lippincott Williams & Wilkins. All rights reserved. All abstracts from the Fifth International Congress Drug Therapy in HIV Infection, appearing on the AEGiS web site, are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Lippincott Williams & Wilkins. You may not alter or remove any trademark, copyright or other notice. However, provided that you maintain all copyright and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only.

http://www.aidsonline.com http://www.ovid.com

This information is designed to support, not replace, the relationship that exists between you and your doctor. ©1980, 2005. AEGiS.